SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations ...

Bristol Myers Squibb BMY and Amgen AMGN are among the largest global biotechnology companies with broad and diverse ...

DURHAM, N.C., November 25, 2025--(BUSINESS WIRE)--Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results from a ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...

(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...

Patients receiving Repatha achieved a median LDL cholesterol level of 45 mg/dL compared to 109 mg/dL in the placebo group. "Repatha has once again demonstrated its ability to protect patients from the ...

THOUSAND OAKS, Calif., Nov. 8, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® (evolocumab) achieved ...